Research & Literature

Current Understanding of the Role of Complement in IgA Nephropathy.

Maillard N, Wyatt RJ, Julian BA, et al.

Journal of the American Society of Nephrology : JASN 2015; (26(7)):1503-12 doi:10.1681/ASN.2014101000.

Clinicopathologic features of IgA-dominant infection-associated glomerulonephritis: a pooled analysis of 78 cases.

Bu R, Li Q, Duan ZY, et al.

American journal of nephrology 2015; (41(2)):98-106 doi:10.1159/000377684.

Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression.

Chakera A, MacEwen C, Bellur SS, et al.

Journal of nephrology 2016; (29(3)):367-375 doi:10.1007/s40620-015-0227-8.

The MEST score provides earlier risk prediction in lgA nephropathy.

Barbour SJ, Espino-Hernandez G, Reich HN, et al.

Kidney international 2016; (89(1)):167-75.

IgA nephropathy and infections.

Rollino C, Vischini G, Coppo R

Journal of nephrology 2016; (29(4)):463-8 doi:10.1007/s40620-016-0265-x.

[Clinical and pathological analysis of IgA nephropathy with acute kidney injury].

Chen MG, Ye XH, Liang HY, Yang Q

Zhonghua er ke za zhi = Chinese journal of pediatrics 2016; (54(8)):610-3 doi:10.3760/cma.j.issn.0578-1310.2016.08.012.

A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy.

Haas M, Verhave JC, Liu ZH, et al.

Journal of the American Society of Nephrology : JASN 2017; (28(2)):691-701 doi:10.1681/ASN.2016040433.

Staphylococcus Infection-Associated GN - Spectrum of IgA Staining and Prevalence of ANCA in a Single-Center Cohort.

Satoskar AA, Suleiman S, Ayoub I, et al.

Clinical journal of the American Society of Nephrology : CJASN 2017; (12(1)):39-49 doi:10.2215/CJN.05070516.

Clinical outcomes of IgA nephropathy patients with different proportions of crescents.

Zhang W, Zhou Q, Hong L, et al.

Medicine 2017; (96(11)):e6190 doi:10.1097/MD.0000000000006190.

Rapidly progressive glomerulonephritis due to anti-glomerular basement membrane disease accompanied by IgA nephropathy: An unusual association.

Annamalai I, Chandramohan G, Srinivasa Prasad ND, et al.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2017; (28(6)):1404-1407 doi:10.4103/1319-2442.220866.

Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy.

Placzek WJ, Yanagawa H, Makita Y, et al.

PloS one 2018; (13(1)):e0190967 doi:10.1371/journal.pone.0190967.

Treatment of IgA nephropathy: Recent advances and prospects.

Coppo R

Nephrologie & therapeutique 2018; (14 Suppl 1()):S13-S21 doi:10.1016/j.nephro.2018.02.010.

Epidemiology of IgA Nephropathy: A Global Perspective.

Schena FP, Nistor I

Seminars in nephrology 2018; (38(5)):435-442 doi:10.1016/j.semnephrol.2018.05.013.

Relationship between renal CD68+ infiltrates and the Oxford Classification of IgA nephropathy.

Soares MF, Genitsch V, Chakera A, et al.

Histopathology 2019; (74(4)):629-637 doi:10.1111/his.13768.

A Case of Hepatic Glomerulosclerosis with Monoclonal IgA1-κ Deposits.

Okabayashi Y, Tsuboi N, Nakaosa N, et al.

Case reports in nephrology 2018; (2018()):4748357 doi:10.1155/2018/4748357.

Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update.

Coppo R, D'Arrigo G, Tripepi G, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2020; (35(6)):1002-1009 doi:10.1093/ndt/gfy302.

The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.

Rizk DV, Maillard N, Julian BA, et al.

Frontiers in immunology 2019; (10()):504 doi:10.3389/fimmu.2019.00504.

Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.

Barbour SJ, Coppo R, Zhang H, et al.

JAMA internal medicine 2019; (179(7)):942-952 doi:10.1001/jamainternmed.2019.0600.

Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy.

Cassol CA, Bott C, Nadasdy GM, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2020; (35(12)):2123-2129 doi:10.1093/ndt/gfz152.

Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1.

Rizk DV, Saha MK, Hall S, et al.

Journal of the American Society of Nephrology : JASN 2019; (30(10)):2017-2026 doi:10.1681/ASN.2018111156.

Association between neutrophil-lymphocyte & platelet lymphocyte ratios with prognosis & mortality in rapidly progressive glomerulonephritis.

Toraman A, Neşe N, Özyurt BC, Kürşat S

The Indian journal of medical research 2019; (150(4)):399-406 doi:10.4103/ijmr.IJMR_1234_17.

Autoantibodies Specific for Galactose-Deficient IgA1 in IgA Vasculitis With Nephritis.

Suzuki H, Moldoveanu Z, Julian BA, et al.

Kidney international reports 2019; (4(12)):1717-1724 doi:10.1016/j.ekir.2019.08.015.

Clinical Profile and Outcome of IgA Nephropathy from a Tertiary Care Hospital in North India.

Jaryal A, Vikrant S

The Journal of the Association of Physicians of India 2020; (68(3)):20-22.

Clinicopathologic features of infection-related glomerulonephritis with IgA deposits: a French Nationwide study.

Miquelestorena-Standley E, Jaulerry C, Machet MC, et al.

Diagnostic pathology 2020; (15(1)):62 doi:10.1186/s13000-020-00980-6.

The correlation analysis between the Oxford classification of Chinese IgA nephropathy children and renal outcome - a retrospective cohort study.

Wu H, Xia Z, Gao C, et al.

BMC nephrology 2020; (21(1)):247 doi:10.1186/s12882-020-01913-7.

Progress in Pathogenesis of Immunoglobin A Nephropathy.

Stanley JC, Deng H

Cureus 2020; (12(6)):e8789 doi:10.7759/cureus.8789.

Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies.

He JW, Zhou XJ, Lv JC, Zhang H

Theranostics 2020; (10(25)):11462-11478 doi:10.7150/thno.49778.

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.

Tuttle KR, Brosius FC, Cavender MA, et al.

Diabetes 2021; (70(1)):1-16 doi:10.2337/dbi20-0040.

Inflammatory Bowel Disease Is More Common in Patients with IgA Nephropathy and Predicts Progression of ESKD: A Swedish Population-Based Cohort Study.

Rehnberg J, Symreng A, Ludvigsson JF, Emilsson L

Journal of the American Society of Nephrology : JASN 2021; (32(2)):411-423 doi:10.1681/ASN.2020060848.

Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy.

Moldoveanu Z, Suzuki H, Reily C, et al.

Journal of autoimmunity 2021; (118()):102593 doi:10.1016/j.jaut.2021.102593.

Systolic blood pressure and chronic kidney disease progression in patients with primary glomerular disease.

Kim HW, Park JT, Joo YS, et al.

Journal of nephrology 2021; (34(4)):1057-1067 doi:10.1007/s40620-020-00930-x.

[Chronic kidney injury in patients with liver diseases - Reappraising pathophysiology and treatment options].

Scurt FG, Bose K, Canbay A, et al.

Zeitschrift fur Gastroenterologie 2021; (59(6)):560-579 doi:10.1055/a-1402-1502.

Supportive Management of IgA Nephropathy With Renin-Angiotensin Blockade, the AIIMS Primary IgA Nephropathy Cohort (APPROACH) Study.

Bagchi S, Mani K, Swamy A, et al.

Kidney international reports 2021; (6(6)):1661-1668 doi:10.1016/j.ekir.2021.02.018.

The Association of the Oxford Classification Score with Longitudinal Estimated Glomerular Filtration Rate Decline in Patients with Immunoglobulin A Nephropathy: A Mixed-Method Study.

Xu R, Li Z, Cao T, et al.

International journal of general medicine 2021; (14()):2655-2663 doi:10.2147/IJGM.S313333.

IgA Nephropathy: Core Curriculum 2021.

Pattrapornpisut P, Avila-Casado C, Reich HN

American journal of kidney diseases : the official journal of the National Kidney Foundation 2021; (78(3)):429-441 doi:10.1053/j.ajkd.2021.01.024.

Indian scenario of IgA nephropathy: a systematic review and meta-analysis.

Khairwa A

African health sciences 2021; (21(1)):159-165 doi:10.4314/ahs.v21i1.21.

Aberrantly Glycosylated IgA1 in IgA Nephropathy: What We Know and What We Don't Know.

Ohyama Y, Renfrow MB, Novak J, Takahashi K

Journal of clinical medicine 2021; (10(16)) doi:10.3390/jcm10163467.

Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.

Rovin BH, Adler SG, Barratt J, et al.

Kidney international 2021; (100(4)):753-779 doi:10.1016/j.kint.2021.05.015.

Collectin11 and Complement Activation in IgA Nephropathy.

Wei M, Guo WY, Xu BY, et al.

Clinical journal of the American Society of Nephrology : CJASN 2021; (16(12)):1840-1850 doi:10.2215/CJN.04300321.

The microbiome and IgA nephropathy.

Haniuda K, Gommerman JL, Reich HN

Seminars in immunopathology 2021; (43(5)):649-656 doi:10.1007/s00281-021-00893-6.

Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort.

Alexander S, Varughese S, Franklin R, et al.

Kidney international reports 2022; (7(2)):305-318 doi:10.1016/j.ekir.2021.11.012.

Seven suggestions for successful SGLT2i use in glomerular disease - a standalone CKD therapy?

McQuarrie EP, Gillis KA, Mark PB

Current opinion in nephrology and hypertension 2022; (31(3)):272-277 doi:10.1097/MNH.0000000000000786.

Glomerular deposition of galactose-deficient IgA1-containing immune complexes via glomerular endothelial cell injuries.

Makita Y, Suzuki H, Nakano D, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2022; (37(9)):1629-1636 doi:10.1093/ndt/gfac204.

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.

Yau K, Dharia A, Alrowiyti I, Cherney DZI

Kidney international reports 2022; (7(7)):1463-1476 doi:10.1016/j.ekir.2022.04.094.

Validation of two IgA nephropathy risk-prediction tools using a cohort with a long follow-up.

Haaskjold YL, Lura NG, Bjørneklett R, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2023; (38(5)):1183-1191 doi:10.1093/ndt/gfac225.

Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.

Tsai WC, Hsu SP, Chiu YL, et al.

BMJ open 2022; (12(10)):e060655 doi:10.1136/bmjopen-2021-060655.

IgA Nephropathy: Pleiotropic impact of Epstein-Barr virus infection on immunopathogenesis and racial incidence of the disease.

Mestecky J, Julian BA, Raska M

Frontiers in immunology 2023; (14()):1085922 doi:10.3389/fimmu.2023.1085922.

Molecular insight in intrarenal inflammation affecting four main types of cells in nephrons in IgA nephropathy.

Zhang H, Deng Z, Wang Y

Frontiers in medicine 2023; (10()):1128393 doi:10.3389/fmed.2023.1128393.

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.

Heerspink HJL, Radhakrishnan J, Alpers CE, et al.

Lancet (London, England) 2023; (401(10388)):1584-1594 doi:10.1016/S0140-6736(23)00569-X.

The incidence and prevalence of IgA nephropathy in Europe.

Willey CJ, Coppo R, Schaefer F, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2023; (38(10)):2340-2349 doi:10.1093/ndt/gfad082.

IgA nephropathy: the lectin pathway and implications for targeted therapy.

Barratt J, Lafayette RA, Zhang H, et al.

Kidney international 2023; (104(2)):254-264 doi:10.1016/j.kint.2023.04.029.

IgA Nephropathy - Beyond the Renal Cortex.

Kirushnan B, Raju B, Kurien AA

Indian journal of nephrology 2023; (33(3)):213-215 doi:10.4103/ijn.ijn_358_21.

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.

Lafayette R, Kristensen J, Stone A, et al.

Lancet (London, England) 2023; (402(10405)):859-870 doi:10.1016/S0140-6736(23)01554-4.

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.

Rovin BH, Barratt J, Heerspink HJL, et al.

Lancet (London, England) 2023; (402(10417)):2077-2090 doi:10.1016/S0140-6736(23)02302-4.

Points of view in nephrology: personalized management of IgA nephropathy, beyond KDIGO.

Trimarchi H, Fervenza FC, Coppo R

Journal of nephrology 2024; (37(3)):739-745 doi:10.1007/s40620-023-01833-3.

Liver Disease-Associated Glomerulopathies.

Kanduri SR, Peleg Y, Wadhwani S

Advances in kidney disease and health 2024; (31(2)):147-156 doi:10.1053/j.akdh.2023.11.002.

Albuminuria predicts kidney events in IgA nephropathy.

Faucon AL, Lundberg S, Lando S, et al.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2025; (40(3)):465-474 doi:10.1093/ndt/gfae085.

Navigating Adult-Onset IgA Vasculitis-Associated Nephritis.

Gan MY, Chua FZY, Chang ZY, et al.

Life (Basel, Switzerland) 2024; (14(8)) doi:10.3390/life14080930.

Short-Term Outcomes of Infection-Related Glomerulonephritis in Diabetes Mellitus.

T S A, Kaliaperumal T, Fernando E, et al.

Cureus 2024; (16(8)):e67238 doi:10.7759/cureus.67238.

Adenovirus: a possible trigger for IgA vasculitis in children.

Mannu A, Vasudevan B, Kashif AW, Kumari L

BMJ case reports 2025; (18(2)) doi:10.1136/bcr-2024-262856.

IgA Vasculitis and IgA Nephropathy: Two Sides of the Same Coin?

Pillebout E

Seminars in nephrology 2024; (44(5)):151571 doi:10.1016/j.semnephrol.2025.151571.

Prognostic Utility of the MEST-C Score Combined With Clinical Parameters in Hispanic Patients With IgA Nephropathy.

Alza-Arcila L, Echeverri-Fernández E, Restrepo-Escobar M, et al.

International journal of nephrology 2025; (2025()):6974280 doi:10.1155/ijne/6974280.

The prevalence of immunoglobulin A nephropathy in the European Union and the impact of the COVID-19 pandemic: an estimation approach utilizing the kidney biopsy frequency.

Buisker J, Behr S, Kubesch NJ, et al.

Clinical kidney journal 2025; (18(4)):sfaf068 doi:10.1093/ckj/sfaf068.

SGLT2 Inhibitors in Glomerulonephritis: Beyond Nephroprotection?

Del Vecchio L, Peiti S, Pucci Bella G, Locatelli F

Journal of clinical medicine 2025; (14(10)) doi:10.3390/jcm14103533.

The Association of Proteinuria Target Achievement Timing and Stability with Adverse Kidney Outcomes among Patients with IgA Nephropathy: A Cohort Study.

Li R, Hui M, Chen P, et al.

American journal of nephrology 2026; (57(4)):409-425 doi:10.1159/000547868.

Successful targeting of the alternative complement cascade with iptacopan for the treatment of IgA nephropathy: a case report.

Ingold L, Dickenmann M, Menter T, et al.

Swiss medical weekly 2025; (155()):4435 doi:10.57187/s.4435.

Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).

Floege J, Barratt J, Cook HT, et al.

Kidney international 2025; (108(4)):548-554 doi:10.1016/j.kint.2025.04.003.

Novel therapies improve prognosis of IgAN and limit the applicability of the International IgA Nephropathy Prediction Tool.

Shen X, Chen P, Liu L, et al.

Clinical kidney journal 2025; (18(9)):sfaf251 doi:10.1093/ckj/sfaf251.

Biopsy-proven glomerular diseases: a systematic review of global kidney biopsy registries.

Covic A, Brinza C, Burlacu A, et al.

Journal of nephrology 2025; (38(9)):2571-2585 doi:10.1007/s40620-025-02449-5.

Rapidly Progressive IgA Nephropathy in a Patient with Systemic Lupus Erythematosus and Chronic Hepatitis B: A Case Report.

Kleinová P, Graňák K, Blichová T, et al.

Reports (MDPI) 2025; (8(4)) doi:10.3390/reports8040220.

Supportive Evidence of Surrogate End Points Based on Treatment Effect of Corticosteroid in IgA Nephropathy.

Sasaki T, Tsuboi N, Koike K, et al.

Kidney international reports 2026; (11(2)):103588 doi:10.1016/j.ekir.2025.09.002.

IgA Nephropathy in Adults: A Review.

Stoneman S, Teh JW, O'Shaughnessy MM

JAMA 2026; (335(9)):799-813 doi:10.1001/jama.2025.25020.

Efficacy and safety of budesonide for the treatment of IgA nephropathy: a systematic review and meta-analysis.

Nabi R, Ansab M, Hussain A, et al.

International urology and nephrology 2026; (58(9)):3795-3811 doi:10.1007/s11255-026-05043-1.

Advances in Novel Biologics Targeting BAFF/APRIL in the Treatment of IgA Nephropathy.

Xu Y, Mo Y, Xu Y

Cells 2026; (15(3)) doi:10.3390/cells15030240.

IgA Nephropathy: Mechanisms, Risk Stratification, and Precision Therapy.

Alobaidi S

Diagnostics (Basel, Switzerland) 2026; (16(9)) doi:10.3390/diagnostics16091259.

IgA Dominant Infection Related Glomerulonephritis Mimicking Primary IgA Nephropathy in Methicillin-Sensitive Staphylococcus aureus Osteomyelitis.

Klor B, Acharya PC, Cunningham I, et al.

International journal of nephrology and renovascular disease 2026; (19()):578405 doi:10.2147/IJNRD.S578405.

The value of sound touch elastography in the noninvasive staging of fibrosis in IgA nephropathy.

Chen RR, Lan ZK, Huang WJ, et al.

BMC medical imaging 2026; (26(1)).

Breaking tolerance in the glomerulus: complement as a driver and therapeutic target in IgA nephropathy.

Lu CL, Yang CC, Wu CC, Lu KC

Frontiers in medicine 2026; (13()):1896069 doi:10.3389/fmed.2026.1896069.

Successful hemodialysis withdrawal with glucocorticoid treatment after achieving infection control in a case of crescentic IgA-dominant staphylococcus-associated glomerulonephritis.

Nishiyama Y, Matsumura M, Yasui Y, et al.

CEN case reports 2026; (15(5)).